经动脉化疗栓塞术市场规模、份额及成长分析（依手术类型、产品类型、适应症、最终用户和地区）－2025 年至 2032 年产业预测

预计 2023 年经动脉化疗栓塞术 (TACE) 市场规模将达到 102 亿美元，并从 2024 年的 106.6 亿美元增长到 2032 年的 151.6 亿美元，预测期内（2025-2032 年）的复合年增长率为 4.5%。

全球经动脉化疗栓塞术 (TACE) 市场正在应对因肝炎感染、饮酒和非酒精性脂肪肝等因素导致的肝癌盛行率上升，导致消费者偏好因治疗肝臟肿瘤的微创方法而改变。医疗技术的创新使得 TACE 手术更加复杂、更准确、成本更低，从而增加了需求。人们对肝癌症状以及早期诊断重要性的认识不断提高，尤其是对于中期肝癌患者，这鼓励他们儘早寻求治疗。然而，市场动态因地区而异，并受到医疗保健基础设施、风险因素发生率、法律规范等的影响。由于肝癌发生率高，亚太地区，尤其是中国，出现了显着的成长。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术进步

动脉化疗栓塞术市场规模（依手术类型和复合年增长率） (2025-2032)

• 市场概览
• 常规TACE
• DEB-TACE

动脉化疗栓塞市场规模（依产品类型和复合年增长率） (2025-2032)

• 市场概览
• 化疗
• 放射治疗剂
• 药物释放型颗粒

动脉化疗栓塞市场规模（按适应症和复合年增长率） (2025-2032)

• 市场概览
• 不可切除的肝细胞癌
• 早期肝细胞癌

动脉化疗栓塞市场规模（依最终使用者和复合年增长率）(2025-2032)

• 市场概览
• 医院和诊所
• 癌症研究中心

动脉化疗栓塞术市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Meril Life Sciences（India）
• MicroPort（China）
• Terumo Corporation（Japan）
• Ethicon（Johnson & Johnson）（United States）
• Neusoft Medical Systems Co., Ltd.（China）
• Merit Medical Systems, Inc.（United States）
• Guerbet Group（France）
• AngioDynamics, Inc.（United States）
• Boston Scientific（United States）
• Medtronic（Ireland）
• Beckton Dickinson（United States）
• Cook Group（United States）
• HealthTronics（United States）
• IceCure Medical（Israel）
• Profound Medical（Canada）
• Siemens Healthineers（Germany）
• GE Healthcare（United States）
• Philips Healthcare（Netherlands）
• Sirtex Medical（Australia）
• BTG plc（United Kingdom）

结论和建议

Transarterial Chemoembolization Market size was valued at USD 10.2 billion in 2023 and is poised to grow from USD 10.66 billion in 2024 to USD 15.16 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

The global transarterial chemoembolization (TACE) market is experiencing a shift in consumer preferences due to its minimally invasive approach to treating hepatoma, in response to the rising prevalence of liver cancer driven by factors such as hepatitis infections, alcohol use, and non-alcoholic fatty liver disease. Innovations in medical technology have led to more sophisticated TACE procedures, enhancing accuracy and reducing costs, thereby boosting demand. Increased awareness regarding liver cancer symptoms and the importance of early diagnosis is prompting patients to seek treatment earlier, particularly for intermediate-grade cases. However, market dynamics vary by region, influenced by healthcare infrastructure, risk factor incidence, and regulatory frameworks, with significant growth observed in the Asia-Pacific region due to higher liver cancer rates, notably in China.

Top-down and bottom-up approaches were used to estimate and validate the size of the Transarterial Chemoembolization market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Transarterial Chemoembolization Market Segments Analysis

Global Transarterial Chemoembolization Market is segmented by Procedure Type, Product Type, Indication, End-User and region. Based on Procedure Type, the market is segmented into Conventional TACE and DEB-TACE. Based on Product Type, the market is segmented into Chemotherapeutic Agents, Radiotherapeutic Agents and Drug-eluting Particles. Based on Indication, the market is segmented into Unresectable HCC and Early-Stage HCC. Based on End-User, the market is segmented into Hospitals and Clinics and Cancer Research Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Transarterial Chemoembolization Market

The Transarterial Chemoembolization (TACE) market is being propelled by the rising global prevalence of liver cancer, which necessitates effective treatment options. In addition, advancements in medical technology are enhancing the precision and effectiveness of these therapeutic procedures, influencing both healthcare providers and patients to opt for TACE. The appeal of minimally invasive techniques plays a significant role in the growth of this market, as they minimize discomfort and pain compared to conventional treatment approaches. As the demand for innovative and less intrusive cancer treatment continues to grow, TACE is emerging as a favored choice among patients and oncologists alike.

Restraints in the Transarterial Chemoembolization Market

The Transarterial Chemoembolization (TACE) market faces significant challenges stemming from the diverse nature of liver cancer patients and their varied responses to treatment. This complexity necessitates a tailored approach to TACE, hindering its widespread adoption. Additionally, stringent regulations surrounding the approval and reimbursement of medical procedures further constrain market growth. Variations in reimbursement policies and lengthy regulatory approval processes can impede the integration of TACE into standard healthcare practices, ultimately limiting its accessibility and use among patients. Consequently, these factors collectively act as significant restraints on the TACE market, affecting its overall development and implementation.

Market Trends of the Transarterial Chemoembolization Market

The Transarterial Chemoembolization (TACE) market is witnessing a significant trend towards personalized medicine, which emphasizes tailored treatment approaches for liver cancer patients. Healthcare providers are increasingly exploring customized TACE strategies based on individual patient characteristics, overall health status, and specific tumor types. This shift aligns with the broader movement toward precision medicine, aiming to optimize patient outcomes through bespoke therapies. Additionally, technological innovations are revolutionizing the TACE landscape, with ongoing research focused on enhancing the precision and efficacy of treatment. Advances in embolic agents, drug-eluting bead technologies, and imaging tools are enabling more targeted interventions, ensuring that the therapeutic impact on cancerous tissues is maximized while minimizing harm to surrounding healthy organs. This dual trend of personalization and technology integration is poised to drive growth in the TACE market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Transarterial Chemoembolization Market Size by Procedure Type & CAGR (2025-2032)

• Market Overview
• Conventional TACE
• DEB-TACE

Global Transarterial Chemoembolization Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Chemotherapeutic Agents
• Radiotherapeutic Agents
• Drug-eluting Particles

Global Transarterial Chemoembolization Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Unresectable HCC
• Early-Stage HCC

Global Transarterial Chemoembolization Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals and Clinics
• Cancer Research Centers

Global Transarterial Chemoembolization Market Size & CAGR (2025-2032)

• North America (Procedure Type, Product Type, Indication, End-User)
  • US
  • Canada
• Europe (Procedure Type, Product Type, Indication, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Procedure Type, Product Type, Indication, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Procedure Type, Product Type, Indication, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Procedure Type, Product Type, Indication, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Meril Life Sciences (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroPort (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ethicon (Johnson & Johnson) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neusoft Medical Systems Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merit Medical Systems, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guerbet Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AngioDynamics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckton Dickinson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cook Group (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HealthTronics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IceCure Medical (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Profound Medical (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sirtex Medical (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BTG plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations